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Background: The bacterial contamination of nebulizers represents a major problem for cystic ﬁbrosis (CF) patients that can lead to reduced
nebulizer performance and increase the risk of patient reinfection by the contaminating bacteria.
Objective: We investigated the potential use of squalamine, a broad-spectrum antimicrobial compound, as a nebulizer disinfectant.
Methods: Pari LC nebulizers were artiﬁcially contaminated with a suspension of bacteria (Staphylococcus aureus and Pseudomonas aeruginosa;
108 CFU/mL) and fungi (Candidida albicans and Aspergilus niger; 107 CFU/mL) and then disinfected by immersion in squalamine solution for
20 min. Glutaraldehyde and Korsolex peracetic acid were used as disinfectant controls.
Result: We found that 0.5 g/L squalamine reduced the levels of viable S. aureus and P. aeruginosa by 5 log10 and the level of viable C. albicans by 4
log10 after 20 min. A concentration of 2 g/Lwas needed to reduce the level ofA. niger cells by 4 log10 in 6 hours. Finally, a formulation of squalamine in
the form of a soluble disinfecting tablet containing 2.5% (w/w) squalamine was developed and successfully applied for nebulizer disinfection.
Conclusion: Our results suggest that aminosterol derivatives may be used by CF patients for rapid and easy home nebulizer disinfection and that
soluble tablets may be developed for this purpose.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Nebulizer; Cystic ﬁbrosis (CF); Aminosterol derivatives; Disinfection; Squalamine1. Introduction
Cystic fibrosis (CF) is characterized by recurrent lung
infections that require repeated inhaled therapies using devices,
namely nebulizers, that transform liquid drug formulations into
aerosols that are inhaled by the patient [1–3]. Several types of
compounds can be used in aerosol therapies, such as antibiotics,
bronchodilators and mucolytics [4]. Because nebulizers are
frequently used by the patients for long periods of time, microbial
contamination generally occurs. This contamination is a seri-
ous problem, leading to reduced nebulizer performance and
increasing the risk of patient reinfection [1,5–7]. Thus, to prevent⁎ Corresponding authors. Tel.: +33 689271645.
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doi:10.1016/j.jcf.2012.05.006the microbial contamination of nebulizers, these devices should
be disinfected [8]. However, few guidelines for nebulizer
disinfection are available [8]; some recommend soaking the
device in vinegar solution, boiling water [9,10] or hypochlorite
solution [11,12]. Such procedures are not easy or convenient for
patients who should disinfect their nebulizer every day. Simple
procedures should be developed to facilitate routine nebulizer
disinfection. These procedures should not involve complicated
cleaning procedures that are rarely performed by patients and/or
their families. In this context, squalamine has recently been
described to possess broad-spectrum antimicrobial properties
against various multidrug-resistant bacterial and fungal isolates
recovered from CF patients [13,14]. It has recently been reported
that squalamine acts as a membrane-active molecule targeting
bacterial membrane integrity [15]. Because of the uniquemode of
action of squalamine, which acts as a detergent, it appears to haveby Elsevier B.V. All rights reserved.
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fungi that are usually recovered from the sputum samples of CF
patients [15]. The broad-spectrum antimicrobial activity of
squalamine suggests that this compoundmay be a good candidate
for development as a disinfecting agent. In the present study, we
evaluated for the first time the suitability of an aqueous solution
of squalamine for home nebulizer disinfection. Squalamine
was evaluated using Pseudomonas aeruginosa, Staphylococcus
aureus, Candidida albicans and Aspergilus niger as reference
strains using a protocol recommended by European standards. In
addition, water-soluble squalamine tablets were developed and
tested in a simple and rapid cleaning and disinfecting process.
2. Materials and methods
2.1. Microbial strains and general procedures
The antimicrobial activity of squalamine was determined in
duplicate with the broth microdilution method as previously
described [16]. P. aeruginosa DSM 939 (ATCC 15442),
S. aureus DSM 799 (ATCC 6538), Candida albicans DSM
1386 (ATCC 10231), and Aspergillus niger ATCC 16404 were
used as reference strains according to the guidelines of the
French and European standards (NF EN 1040 and NF EN 1275,
1997) [17–19]. The bacteria and fungi were cultivated on
trypticase soy agar (TSA) and Sabouraud agar for 24 hours and
48 hours, respectively. Bactericidal activity was defined as a
reduction of 5 log10 during a defined time for S. aureus (ATCC
6538) and P. aeruginosa (ATCC 15442) using a standard
concentration of 108 CFU/mL [17–19]. Fungicidal activity was
defined as a reduction of 4 log10 for C. albicans (ATCC 10231)
and A. niger ATCC 16404 using a standard concentration of
107 CFU/mL using a dilution-neutralization or membrane
filtration method (NF EN 1040 and NF EN 1275, 1997).
2.2. Drug compounds
Squalamine was a generous gift from Pr. M. Zasloff
(Georgetown University, Washington, USA). Stock solutions
were prepared in sterile water. The stock solution was subsequentlyNebulizer artificially 
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water
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Fig. 1. Model of contamination andiluted to 250 mg/L for use as a working solution. Korsolex
peracetic acid (Bode Chemie GmbH, Hamburg, Germany) and
glutaraldehyde (2%) (Electron Microscopy Sciences, Hatfield,
USA) were used as positive controls for disinfection, as recom-
mended by CCLIN 2001 for endoscope disinfection [20]. In all
cases the disinfection protocol remains the same.
2.3. Disinfection protocol
Microbial contamination of the nebulizer was mimicked by
the immersion of the inner part of the nebulizer (Pari LC,
SPRINT SP, Pari, Germany) in a bacterial suspension prepared
in Mueller Hinton broth containing 1.108 to 5.108 CFU/mL of
bacteria (NF EN 1040, 1997) (Fig. 1). Then, disinfection was
performed by soaking the same part of the nebulizer in sterile
water containing predetermined concentrations of squalamine,
depending on the strains used. For fungi, 1.107 to 5.107 CFU/mL
suspensions (NF EN 1275, 1997) were prepared in Sabouraud
broth, and after incubation in the fungal suspension, the nebulizer
was immersed in sterile water containing squalamine. The
nebulizer was then soaked in two successive sterile water
solutions and removed. The number of bacteria or fungi in the
second water bath was then determined. The enumeration of
bacterial and fungal colonies was performed with TSA for
bacteria and malt extract agar for fungi. The bactericidal and
fungicidal test was performed three times in independent ex-
periments, and each bacterium and fungus was tested separately.
The concentration of squalamine was increased until bactericidal
or fungicidal activity was obtained. The defined disinfection
period in the reference procedure [21–23] was 20 min, and the
disinfection period was extended to 6 hours for A. niger.
2.4. The production of squalamine tablets
A 20 g batch size of the tablets formulation was prepared.
The mixture was prepared in a Turbula Type T 20 mixer
(Switzerland), and the tablets were manufactured with an
alternative tablet press (Korsch Erwika Type EKO, Germany).
All of the raw materials were sieved before squalamine (0.5 g)
was mixed with microcrystalline cellulose (7.2 g), lactose (10 g),in 
20 min to 6 hours
hours
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d disinfection of a nebulizer.
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(0.04 g). Then, sieved magnesium stearate was added, and the
mixture was mixed. The final blend was compressed on an
alternative tablet press equipped with 8.0 mm punches. Excipi-
ents with a particle size amenable to direct compression were
used. The tablets were stored in a low-density polyethylene
bottle. The disinfection experiments were performed less than
10 days after the squalamine tablets were formulated.Fig. 2. Results of the disinfection of a nebulizer contaminated with bacteria
(A) or fungi (B) with squalamine solution.3. Results
In a preliminary set of experiments, the MIC values for
squalamine against the selected reference bacteria and fungi as
well as more resistant bacteria such as Burkholderia cepacia
and Achromobacter xylosoxidans were determined. The MIC
values against reference strains were 2, 4, 16 and 16 mg/L for
S. aureus, P. aeruginosa, C. albicans, and A. niger, respec-
tively (Table 1). In addition, we demonstrated that a 0.5 g/L
dose of squalamine for 1 hour led to a reduction of 8 log10 for
S. aureus and P. aeruginosa from an initial bacterial suspension
of 108 CFU/mL (Fig. 3).
The bactericidal and fungicidal activities were determined
through artificially contaminating a nebulizer with a bacterial
suspension (1.108 to 5. 108 CFU/mL) or a fungal suspension
(1.107 to 5. 107 CFU/mL) and then disinfecting the nebulizer
through subsequent immersion in a squalamine solution.We used
20 min for disinfecting the nebulizer with squalamine as recom-
mended by the European standard, whereas 15 min was used for
Korsolex PAA and the glutaraldehyde (2%) solution as specified
by the supplier (Fig. 2).
In the first attempt, we determined that an 80 mg/mL dose
for 20 min led to reductions of 2 and 3 log10 for bacteria,
whereas a reduction of only 2 log10 was obtained for C.
albicans using 190 mg/mL squalamine. No significant decrease
in the number of viable A. niger cells was noted under these
conditions. The reductions in the numbers of bacteria and fungi
at this concentration of squalamine were lower than those
recommended by the standards (5 log10 for bacteria and 4 log10
for fungi). Thus, we increased the squalamine concentration
until the recommended bactericidal and fungicidal activities
were obtained: 5 log10 reductions were obtained for S. aureus
and P. aeruginosa using 210 and 130 mg/L of squalamine for
20 min, respectively, whereas 500 mg/L and 2 g/L were
necessary to obtain reductions of 4 log10 for C. albicans and
A. niger after 20 min and 6 hours, respectively (Fig. 1).Table 1
Antimicrobial activity and, bactericidal and fungicidal doses of squalamine.
Strains MICs (mg/L)
of squalamine
Squalamine dose (mg/L)
for nebulizer disinfection
S. aureus DSM 799 2 210
P. aeruginosa DSM 939 4 130
C. albicans DSM 1386 16 500
A. niger ATCC 16404 16 2000
B. cepacia 8 2000
A. xylosoxidans 64 2000In the case of A. niger, the disinfecting time was first set at
20 min, and the dose was increased to 1 g/L, but no fungicidal
activity was observed under these conditions. In a second set of
experiments, we increased the time to 6 hours, and two doses of
squalamine were used for nebulizer disinfection, 1 mg/mL and
2 mg/mL, leading to reductions of 3 and 4 log10 for this fungal
strain, respectively. Korsolex peracetic acid and 2% glutaral-
dehyde were used as controls for the bactericidal and fungicidal
activities leading to reductions of 5 log10 for bacteria and 4
log10 for fungi.
White to almost white flat, round, soluble squalamine tablets
weighing 200 mg with a hardness of 8.7 Kp containing 2.5%
squalamine were successfully formulated. These tablets had a
disintegration time of 5 min in water at ambient temperature.
Three squalamine tablets dissolved in 50 mL of sterile distilled
water reduced the number of viable bacteria cells by 5 log10Fig. 3. Results of the disinfection of a nebulizer contaminated with S. aureus
and P. aeruginosa bacteria using squalamine solution (0.5 g/L) for 1 hour.
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C. albicans cells by 4 log10 after 20 min.
4. Discussion
Nebulizers are widely used by CF patients and are widely
considered to be a source ofmicrobial contamination to which CF
patients are exposed [21]. Cleaning and disinfection have been
recommended to limit the risk of contamination [7]. Various
methods for nebulizer disinfection have been proposed by
different CF foundations. These methods include daily steeping
in a vinegar solution (2%), boiling in water [9,10], and washing in
a dishwasher at 70 °C [11]. Other methods include immersion in
70% to 90% ethyl or isopropyl alcohol for 5 min [8] and soaking
and rinsing with tap water followed by air drying [22,23]. Sodium
hypochlorite has also been recommended, with different
standards depending on the country. The French CF association
recommends the use of hypochlorite solution with 0.08% active
chlorine for 15 to 30 min, whereas the American CF foundation
recommends the immersion of the infected material in a solution
containing 0.13% active chlorine for 3 min [11]. In 2001,
Rosenfeld et al. were the first to study the contamination of jet
nebulizers with a cocktail of S. aureus and P. aeruginosa and
clean these contaminated nebulizers with tap water at 35 °C for
30 s, followed by drying at room temperature [22]. This cleaning
procedure led to a reduction in the bacterial density to 20 CFU/
mL, whereas the average of the positive control was 105 CFU/
mL [22]. In 2006, a study of the cleaning of ultrasonic nebulizers
found a lower number of contaminated samples when the
nebulizer was disinfected with sodium hypochlorite (100 ppm)
for 1 hour each day than when the nebulizers were disinfected at
intervals of 2–7 days. These results led to the conclusion that the
disinfection of nebulizers should be performed every 24 hours
[24]. More recently, Reychler et al. compared the in vitro
efficiencies of different disinfectants against 16 Gram-positive
and Gram-negative bacteria. The disinfection methods included
exposure to hypochlorite solution (0.02% chlorine), 3.5% acetic
acid, 0.5%Hexanios, or dishwashing detergent (0.5%) for 20 min
and washing in a dishwasher (70 °C). Reductions in the bacterial
loads (reductions of 5 log10) of S. aureus, P. aeruginosa,
Stenotrophomonas maltophilia, A. xylosoxidans and B. cenoce-
pacia were observed for all of the disinfectants used [11]. The
initial concentration of bacteria in the culture broth used for
contamination was 7.3 to 8.2 log10 CFU/mL for all bacteria
except for Burkholderia cenocepacia, which was at 5.2 log10
CFU/mL. Acetic acid (3.5%) was ineffective in disinfecting
S. aureus- and B. cenocepacia-contaminated materials [11].
Monforte et al. demonstrated that proper disinfection could be
achieved by washing the nebulizer in soap and water after use and
immersing the nebulizer in a sodium hypochlorite (1%) solution
until the next use; only 12.5% of the nebulizers of patients who
followed this protocol were contaminated, whereas 60% were
contaminated otherwise [7].
The water sources used for nebulizer rinsing are variable
(distilled water, tap water, and sterile water) and can be a source
of nebulizer contamination, as demonstrated for S. maltophilia,
which can be found in tap water [25].In this work, we demonstrated for the first time the suitability
of squalamine as a disinfecting agent using a nebulizer model. A
5 log10 reduction in the number of viable bacterial cells and a 4
log10 reduction in the number of viable fungal cells are required
for disinfection. In our study, the reduction in the growth of
A. niger required a longer time (6 hours) than the reduction
in bacterial growth. This result could be explained by an
intrinsically higher level of resistance against squalamine for
A. niger [26]. A. niger is a filamentous fungus that can sporulate,
and it is known to be more resistant to glutaraldehyde than other
fungi; 0.5% alkaline glutaraldehyde reduced the number of
A. niger spores by 4 log10 after only 100 min [27]. Moreover,
Vizcaino et al. demonstrated that glutaraldehyde applied to a
scalpel induced corrosion within 2 hours [28].
Generally, children with CF depend on their parents to
perform the nebulizer disinfection. Because the patients use
nebulizers daily, the disinfection methodology must be simple
and practical and should be improved for better compliance [29].
In this study, we developed a simple, rapid and easy method for
home nebulizer disinfection that uses soluble squalamine tablets.
It is noteworthy that the formulated tablets disintegrated in water
in less than 5 min, suggesting that these tablets can be easily used
as a disinfecting agent. Another improvement in this model could
be achieved by preparing effervescent tablets, which may ensure
faster dissolution and a more homogeneous compound dis-
tribution in water. This use of effervescent tablets would be
comparable to the use of disinfecting tablets for the daily
decontamination of feeding bottles. A limitation of our study was
the use of a new nebulizer; older nebulizers fromCF patients may
be more difficult to disinfect if they have irregular surfaces.
Although squalamine remains difficult to synthesize, we have
recently developed a two-step synthesis methodology using
cheap starting materials that allows for the preparation of
numerous bispolyaminosterol squalamine analogs with high
chemical yields. Thus, we believe that such compounds could
be used in the form of tablets for the disinfection of medical
devices at a low cost under simple conditions. Aminosterol de-
rivative tablets would not induce resistance because these
compounds do not select for resistance in bacteria and fungi
due to their mode of action [15]. This disinfection method may
have a positive psychological impact because the patient would
be able to easily and independently disinfect his or her nebulizer.5. Conclusion
In summary, our method is easy because it only requires the
immersion of the contaminated nebulizer in a water solution
containing soluble squalamine tablets for a short time. This
method appears to be highly effective for nebulizer disinfection
under our simple laboratory conditions. It would be interesting
to directly test the activity of aminosterol derivatives or squa-
lamine tablets on contaminated nebulizers used by CF patients
to better evaluate the potential use of these compounds for
nebulizer disinfection. Otherwise, all these results suggest that
squalamine could be added on the EU positive list of dis-
infectants for the use in health care.
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